For brain tumor patients who are resistant to chemotherapy, radiation and existing treatment options, surgery are central to survival.
7D Surgical, one of the leaders in advanced optical technologies and vision-based surgery algorithms, is dedicated to continually improving the standard of patient care.
Their flagship product, the MvIGS technology has the power to obtain hundreds of thousands of virtual fiducials leveraging the patient’s anatomy which allows for immediate cranial registration in just about any surgical position.
The MvIGS has been granted FDA and Health Canada approvals for cranial surgery in 2018, and is already a popular technology among spine and neurosurgeons.
When it comes to brain tumor management, surgery holds a key prognostic factor, particularly because surgeons have to perform an incredibly accurate resection while also margining the proximity of normal tissue and identifying any residual tumors.
One of the executives at 7D Surgical recently stated, “Imagine that on any given day, 27 people are diagnosed with a brain tumor. Sadly, some are inoperable, but where there is hope for recovery, we make it our top priority to turn that hope into reality. More often than we’d think, brain surgeons heavily rely on subjective assessments during such a procedure to help them distinguish the cancer from surrounding normal tissues. This increases the risk of incomplete tumor resection or unwarranted removal of healthy tissue, and that’s where image-guided surgery comes in.”
7D Surgical is looking to expand beyond North America, with Australia and New Zeeland targeted as the next key markets.